{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:17:27Z","timestamp":1788311847185,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible visual impairment among older adults. Although intravitreal anti\u2013vascular endothelial growth factor (anti-VEGF) therapy has improved visual outcomes, real-world effectiveness is often limited by poor adherence and treatment discontinuation. This study evaluated the impact of a structured patient engagement program on treatment adherence, injection persistence, visual outcomes, and patient-reported outcomes in patients receiving anti-VEGF therapy for nAMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This single-center retrospective observational comparative cohort study included 350 patients with nAMD treated between January 2022 and December 2024. Patients received either standard care alone (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009175) or standard care plus a structured patient engagement program (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009175) incorporating individualized education, adherence counseling, appointment reminders, and proactive follow-up communication. Primary outcomes were treatment adherence and injection persistence. Secondary outcomes included best-corrected visual acuity (BCVA), patient satisfaction, and disease understanding.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients enrolled in the engagement program demonstrated significantly better adherence than those receiving standard care. The mean number of missed injection visits was lower (0.51\u2009\u00b1\u20090.68 vs. 1.48\u2009\u00b1\u20091.27;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), and delayed injections exceeding two weeks were less frequent (22.3% vs. 50.9%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Good adherence was achieved in 89.1% of patients in the engagement group compared with 50.3% in the standard care group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), while treatment persistence was higher (90.9% vs. 77.7%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001). Final BCVA was significantly better in the engagement group (0.61\u2009\u00b1\u20090.30 vs. 0.70\u2009\u00b1\u20090.34 LogMAR;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.015), and a greater proportion of patients experienced visual improvement (65.1% vs. 52.6%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.023). Patient satisfaction and disease understanding were also significantly higher among patients receiving the engagement intervention (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001 for both). Safety outcomes were comparable between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A structured patient engagement program was associated with improved treatment adherence, enhanced injection persistence, and better short- to mid-term visual outcomes in patients receiving anti-VEGF therapy for nAMD. These findings support the integration of patient-centered engagement strategies into routine retinal care to optimize real-world treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-026-05045-8","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T12:45:12Z","timestamp":1781959512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of a structured patient engagement program on treatment adherence, injection persistence, and visual outcomes in real-world anti-VEGF therapy for neovascular age-related macular degeneration"],"prefix":"10.1186","volume":"26","author":[{"given":"Lixia","family":"Lan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"issue":"10386","key":"5045_CR1","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(22)02609-5","volume":"401","author":"RH Guymer","year":"2023","unstructured":"Guymer RH, Campbell TG. Age-related macular degeneration. Lancet Elsevier. 2023;401(10386):1459\u201372.","journal-title":"Lancet Elsevier"},{"issue":"2","key":"5045_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","volume":"331","author":"M Fleckenstein","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. 2024;331(2):147\u201357.","journal-title":"JAMA"},{"key":"5045_CR3","doi-asserted-by":"crossref","unstructured":"Vyawahare H, Shinde P. Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment. Cureus. 2022;14(9).","DOI":"10.7759\/cureus.29583"},{"issue":"3","key":"5045_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4068\/cmj.2023.59.3.143","volume":"59","author":"MA Amini","year":"2023","unstructured":"Amini MA, Karbasi A, Vahabirad M, Khanaghaei M, Alizamir A. Mechanistic insight into age-related macular degeneration (AMD): anatomy, epidemiology, genetics, pathogenesis, prevention, implications, and treatment strategies to pace AMD management. Chonnam Med J. 2023;59(3):143.","journal-title":"Chonnam Med J"},{"issue":"2","key":"5045_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","volume":"331","author":"M Fleckenstein","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration. Jama Am Med Association (AMA). 2024;331(2):147.","journal-title":"Jama Am Med Association (AMA)"},{"key":"5045_CR6","unstructured":"Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. Institute of Pharmcology Polish Academy of Sciences. 2006;58(3):353."},{"issue":"5","key":"5045_CR7","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.3758\/s13423-022-02117-w","volume":"29","author":"C Vater","year":"2022","unstructured":"Vater C, Wolfe B, Rosenholtz R. Peripheral vision in real-world tasks: A systematic review. Psychon Bull Rev Springer. 2022;29(5):1531\u201357.","journal-title":"Psychon Bull Rev Springer"},{"issue":"23","key":"5045_CR8","doi-asserted-by":"publisher","first-page":"13053","DOI":"10.3390\/ijms252313053","volume":"25","author":"N Marchesi","year":"2024","unstructured":"Marchesi N, Capierri M, Pascale A, Barbieri A. Different therapeutic approaches for dry and wet AMD. Int J Mol Sci MDPI. 2024;25(23):13053.","journal-title":"Int J Mol Sci MDPI"},{"issue":"3","key":"5045_CR9","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3390\/ijms22031170","volume":"22","author":"A Pugazhendhi","year":"2021","unstructured":"Pugazhendhi A, Hubbell M, Jairam P, Ambati B. Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy. Int J Mol Sci. 2021;22(3):1170. https:\/\/doi.org\/10.3390\/ijms22031170.","journal-title":"Int J Mol Sci"},{"key":"5045_CR10","doi-asserted-by":"crossref","unstructured":"Nur-Najwa S, Zunaina E, Azhany Y, Suhaifi N-N, Yaakub A. Intravitreal anti-vascular endothelial growth factor (Anti-VEGF) therapy for valsalva related sub-internal limiting membrane (Sub-ILM) macular haemorrhage: a case report. Cureus. 2023;15(8).","DOI":"10.7759\/cureus.44420"},{"issue":"14","key":"5045_CR11","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. 2006;355(14):1419\u201331. https:\/\/doi.org\/10.1056\/NEJMoa054481.","journal-title":"N Engl J Med"},{"issue":"20","key":"5045_CR12","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration","year":"2011","unstructured":"Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. 2011;364(20):1897\u2013908. https:\/\/doi.org\/10.1056\/NEJMoa1102673.","journal-title":"N Engl J Med"},{"issue":"12","key":"5045_CR13","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology. 2012;119(12):2537\u201348. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006.","journal-title":"Ophthalmology"},{"issue":"4","key":"5045_CR14","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1016\/j.ophtha.2020.01.029","volume":"127","author":"DF Martin","year":"2020","unstructured":"Martin DF, Maguire MG, Fine SL, Ying G, Jaffe GJ, Grunwald JE, et al. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration. Ophthalmology. 2020;127(4):S135\u201345. https:\/\/doi.org\/10.1016\/j.ophtha.2020.01.029.","journal-title":"Ophthalmology"},{"issue":"6","key":"5045_CR15","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1177\/1120672119880386","volume":"30","author":"M Battaglia Parodi","year":"2020","unstructured":"Battaglia Parodi M, Romano F, Arrigo A, Sacchi R, Scanzi G, Ferri C, et al. Real-life anti\u2013vascular endothelial growth factor treatment for age-related macular degeneration and diabetic macular edema in an Italian tertiary referral hospital. Eur J Ophthalmol. 2020;30(6):1461\u20136. https:\/\/doi.org\/10.1177\/1120672119880386.","journal-title":"Eur J Ophthalmol"},{"issue":"12","key":"5045_CR16","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1007\/s00417-021-05451-2","volume":"259","author":"P Lanzetta","year":"2021","unstructured":"Lanzetta P. Anti-VEGF therapies for age-related macular degeneration: a powerful tactical gear or a blunt weapon? The choice is ours. Graefes Arch Clin Exp Ophthalmol. 2021;259(12):3561\u20137. https:\/\/doi.org\/10.1007\/s00417-021-05451-2.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"5045_CR17","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00417-020-04798-2","volume":"258","author":"C Ehlken","year":"2020","unstructured":"Ehlken C, Ziemssen F, Eter N, Lanzl I, Kaymak H, Lommatzsch A, et al. Systematic review: non-adherence and non-persistence in intravitreal treatment. Graefes Arch Clin Exp Ophthalmol. 2020;258(10):2077\u201390. https:\/\/doi.org\/10.1007\/s00417-020-04798-2.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"5045_CR18","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","volume":"9","author":"MJ Burton","year":"2021","unstructured":"Burton MJ, Ramke J, Marques AP, Bourne RR, Congdon N, Jones I, et al. The lancet global health commission on global eye health: vision beyond 2020. Lancet Glob Health Elsevier. 2021;9(4):e489\u2013551.","journal-title":"Lancet Glob Health Elsevier"},{"issue":"1","key":"5045_CR19","first-page":"905934","volume":"2012","author":"S Barello","year":"2012","unstructured":"Barello S, Graffigna G, Vegni E. Patient engagement as an emerging challenge for healthcare services: mapping the literature. Nurs Res Pract Wiley Online Libr. 2012;2012(1):905934.","journal-title":"Nurs Res Pract Wiley Online Libr"},{"issue":"4","key":"5045_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4274\/tjo.28003","volume":"47","author":"O Polat","year":"2017","unstructured":"Polat O, \u0130nan S, \u00d6zcan S, Do\u011fan M, K\u00fcsbeci T, Yava\u015f GF, et al. Factors Affecting Compliance to Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Age-Related Macular Degeneration. T\u00fcrk Oftalmol Derg. 2017;47(4):205\u201310. https:\/\/doi.org\/10.4274\/tjo.28003.","journal-title":"T\u00fcrk Oftalmol Derg"},{"issue":"10","key":"5045_CR21","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.4103\/ijo.IJO_1866_19","volume":"68","author":"A Kelkar","year":"2020","unstructured":"Kelkar A, Webers C, Shetty R, Kelkar J, Labhsetwar N, Pandit A, et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema. Indian J Ophthalmol. 2020;68(10):2143. https:\/\/doi.org\/10.4103\/ijo.IJO_1866_19.","journal-title":"Indian J Ophthalmol"},{"issue":"8","key":"5045_CR22","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1097\/00005650-199808000-00004","volume":"36","author":"DL Roter","year":"1998","unstructured":"Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care LWW. 1998;36(8):1138\u201361.","journal-title":"Med Care LWW"},{"issue":"1","key":"5045_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication Compliance and Persistence: Terminology and Definitions. Value Health. 2008;11(1):44\u20137. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00213.x.","journal-title":"Value Health"},{"issue":"2","key":"5045_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP, Eldem B, Talks SJ, Hirst C, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmol Elsevier. 2021;128(2):234\u201347.","journal-title":"Ophthalmol Elsevier"},{"key":"5045_CR25","unstructured":"Pessoa BB dos ST. The role of vitreous and vitreoretinal interface in the management of diabetic macular edema. Universidade do Porto (Portugal). 2022."},{"issue":"4","key":"5045_CR26","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3390\/genes15040413","volume":"15","author":"JH Seo","year":"2024","unstructured":"Seo JH, Lee Y. Causal associations of glaucoma and age-related macular degeneration with cataract: a bidirectional two-sample mendelian randomisation study. Genes MDPI. 2024;15(4):413.","journal-title":"Genes MDPI"},{"issue":"1","key":"5045_CR27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13643-023-02261-x","volume":"12","author":"H Shahzad","year":"2023","unstructured":"Shahzad H, Mahmood S, McGee S, Hubbard J, Haque S, Paudyal V, et al. Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis. Syst Rev Springer. 2023;12(1):92.","journal-title":"Syst Rev Springer"},{"issue":"5","key":"5045_CR28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4274\/tjo.31697","volume":"48","author":"A \u00d6zkaya","year":"2018","unstructured":"\u00d6zkaya A, Karaba\u015f L, Alag\u00f6z C, Alk\u0131n Z, Artunay \u00d6, B\u00f6l\u00fckba\u015f\u0131 S, et al. Real-world outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in turkey: a multicenter retrospective study, Bosphorus retina Study Group report 1. Turk J Ophthalmol. 2018;48(5):232.","journal-title":"Turk J Ophthalmol"},{"issue":"5","key":"5045_CR29","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmol Elsevier. 2020;127(5):616\u201336.","journal-title":"Ophthalmol Elsevier"},{"issue":"1","key":"5045_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti\u2013vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes. Ophthalmol Retina Elsevier. 2020;4(1):19\u201330.","journal-title":"Ophthalmol Retina Elsevier"},{"key":"5045_CR31","doi-asserted-by":"crossref","unstructured":"Jelin E, Wisl\u00f8ff T, J\u00f8rstad \u00d8K, Heiberg T, Moe MC. Patient-reported outcome measures in the management of neovascular age-related macular degeneration: a 1-year prospective study. BMJ Open Ophthalmol. BMJ Publishing Group Ltd. 2019;4(1).","DOI":"10.1136\/bmjophth-2019-000353"},{"issue":"2","key":"5045_CR32","first-page":"156","volume":"65","author":"S Ka\u0161telan","year":"2024","unstructured":"Ka\u0161telan S, Pjeva\u010d N, Bra\u0161 M, \u0110or\u0111evi\u0107 V, Pjeva\u010d Kelemini\u0107 N, Mezzich JE. Person-centered care in ophthalmology: current knowledge and perspectives. Croat Med J Sveu\u010dili\u0161te u Zagrebu Medicinski fakultet. 2024;65(2):156\u201360.","journal-title":"Croat Med J Sveu\u010dili\u0161te u Zagrebu Medicinski fakultet"},{"issue":"1","key":"5045_CR33","first-page":"22122","volume":"10","author":"M Morioka","year":"2020","unstructured":"Morioka M, Takamura Y, Nagai K, Yoshida S, Mori J, Takeuchi M, et al. Incidence of endophthalmitis after intravitreal injection of an anti-VEGF agent with or without topical antibiotics. Sci Rep Nat Publishing Group UK Lond. 2020;10(1):22122.","journal-title":"Sci Rep Nat Publishing Group UK Lond"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05045-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05045-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05045-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:08:02Z","timestamp":1788311282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-05045-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5045"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-05045-8","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Nanchang Aier Eye Hospital (Ethical approval No. 2021(004)). All procedures were conducted in accordance with the ethical standards of the institutional research committee and with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"533"}}